IDEAYA Biosciences, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Yujiro S. Hata
- Full Time Employees
- 131
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 7000 Shoreline Court South San Francisco CA United States of America 94080
- IPO Date
- May 23, 2019
- CIK
- 0001676725
- Website
- ideayabio.com
- Similar Companies
- Business
- IDEAYA Biosciences, Inc. is a clinical-stage precision medicine oncology company focused on the discovery, development, and commercialization of targeted therapeutics principally in precision oncology. The company’s core product pipeline includes small-molecule drugs and antibody-drug conjugates (ADCs) centered around synthetic lethality and biomarkers-driven patient selection. Key products in clinical development include darovasertib (IDE196), a protein kinase C (PKC) inhibitor for tumors with GNAQ or GNA11 mutations such as uveal melanoma; IDE397, a methionine adenosyltransferase 2A (MAT2A) inhibitor targeting cancers with MTAP gene deletions; IDE161, a poly(ADP-ribose) glycohydrolase (PARG) inhibitor for tumors with homologous recombination deficiency (HRD); and IDE034, a bispecific B7H3/PTK7 TOP1 antibody-drug conjugate designed for solid tumors expressing these targets. IDEAYA employs integrated biomarker and small molecule drug discovery platforms and collaborates with leading pharmaceutical companies to advance its pipeline globally. The company operates primarily out of South San Francisco, California, and was founded to leverage synthetic lethality approaches to selectively target cancer vulnerabilities while sparing normal cells. Recent major corporate developments include strategic partnerships and collaborations with pharmaceutical companies such as GlaxoSmithKline (GSK), which focuses on IDEAYA’s synthetic lethality programs including MAT2A, Pol Theta, and Werner Helicase, with shared development costs and profit-sharing arrangements. Partnership with Gilead centers on the IDE397 program, and a collaboration with Pfizer supports development of darovasertib. Additionally, in September 2025, IDEAYA entered a global licensing and collaboration agreement with Servier, under which Servier obtained rights to darovasertib outside the U.S., bringing in $210 million upfront plus up to $320 million in milestones, expanding the commercial and clinical development reach of this program worldwide. In December 2025, the U.S. Food and Drug Administration cleared IDEAYA’s investigational new drug application for IDE034, initiating a Phase 1 clinical trial enrolling patients in the first quarter of 2026 targeting multiple solid tumors including lung, colorectal, head and neck, and ovarian cancers. These recent advances underscore IDEAYA’s commitment to advancing potentially first-in-class, precision-guided oncology therapies and expanding its clinical pipeline while strategically leveraging partnerships to enhance global development and commercialization efforts.
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit
IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference
IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial Data
IDEAYA Biosciences, Inc. (IDYA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma
IDEAYA Biosciences Unveils OptimUM-02 Data: Darovasertib/Crizotinib Doubles PFS in Uveal Melanoma
IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal Melanoma Transcript
IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars
Ideaya Biosciences Stock Jumps 15% on Eye Cancer Therapy Trial Results
IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma